Harmonizing the Nomenclature for Therapeutic Aerosol Particle Size

A Proposal

Elizabeth V Hillyer, David B Price, Henry Chrystyn, Richard J Martin, Elliot Israel, Willem M C van Aalderen, Alberto Papi, Omar S Usmani, Nicolas Roche

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Total and regional airway deposition of orally inhaled drugs is determined by the complex interaction of numerous patient- and inhaler-related factors. Particle size (aerodynamic diameter) is considered to be the most important of the aerosol-related factors(1–3); however, the medical literature lacks standard nomenclature to distinguish aerosol particle sizes. There are clear differences in particle behavior and deposition according to size, and hence we believe a strong rationale for clearly denoting the aerosol particle size of orally inhaled, therapeutic aerosols, both in product descriptions and as part of the design and reporting of research in this area
Original languageEnglish
Pages (from-to)111-113
Number of pages3
JournalJournal of aerosol medicine and pulmonary drug delivery
Volume31
Issue number2
Early online date28 Nov 2017
DOIs
Publication statusPublished - 30 Apr 2018

Fingerprint

Aerosols
Particle Size
Terminology
Nebulizers and Vaporizers
Therapeutics
Research Design
Pharmaceutical Preparations

Keywords

  • Letter to the Editor

Cite this

Harmonizing the Nomenclature for Therapeutic Aerosol Particle Size : A Proposal. / Hillyer, Elizabeth V; Price, David B; Chrystyn, Henry; Martin, Richard J; Israel, Elliot; van Aalderen, Willem M C; Papi, Alberto; Usmani, Omar S; Roche, Nicolas.

In: Journal of aerosol medicine and pulmonary drug delivery, Vol. 31, No. 2, 30.04.2018, p. 111-113.

Research output: Contribution to journalArticle

Hillyer, EV, Price, DB, Chrystyn, H, Martin, RJ, Israel, E, van Aalderen, WMC, Papi, A, Usmani, OS & Roche, N 2018, 'Harmonizing the Nomenclature for Therapeutic Aerosol Particle Size: A Proposal', Journal of aerosol medicine and pulmonary drug delivery, vol. 31, no. 2, pp. 111-113. https://doi.org/10.1089/jamp.2017.1396
Hillyer, Elizabeth V ; Price, David B ; Chrystyn, Henry ; Martin, Richard J ; Israel, Elliot ; van Aalderen, Willem M C ; Papi, Alberto ; Usmani, Omar S ; Roche, Nicolas. / Harmonizing the Nomenclature for Therapeutic Aerosol Particle Size : A Proposal. In: Journal of aerosol medicine and pulmonary drug delivery. 2018 ; Vol. 31, No. 2. pp. 111-113.
@article{2ffe612c172442d5b7d91469220e1a9c,
title = "Harmonizing the Nomenclature for Therapeutic Aerosol Particle Size: A Proposal",
abstract = "Total and regional airway deposition of orally inhaled drugs is determined by the complex interaction of numerous patient- and inhaler-related factors. Particle size (aerodynamic diameter) is considered to be the most important of the aerosol-related factors(1–3); however, the medical literature lacks standard nomenclature to distinguish aerosol particle sizes. There are clear differences in particle behavior and deposition according to size, and hence we believe a strong rationale for clearly denoting the aerosol particle size of orally inhaled, therapeutic aerosols, both in product descriptions and as part of the design and reporting of research in this area",
keywords = "Letter to the Editor",
author = "Hillyer, {Elizabeth V} and Price, {David B} and Henry Chrystyn and Martin, {Richard J} and Elliot Israel and {van Aalderen}, {Willem M C} and Alberto Papi and Usmani, {Omar S} and Nicolas Roche",
note = "Acknowledgements: The authors thank the other members of the Small Airways Study Group of the Respiratory Effectiveness Group who participated in discussions about nomenclature for therapeutic aerosol particle size: Dirkje Postma (University of Groningen, Department of Pulmonary Medicine and Tuberculosis, University Medical Center Groningen, the Netherlands, retired), Theresa Guilbert (Cincinnati Children's Hospital and Medical Center, Cincinnati, OH), Jonathan Grigg (Blizard Institute, Queen Mary University London, London, UK), and Wanda Phipatanakul (Boston Children's Hospital and Harvard Medical School, Boston, MA). They also thank Alison Chisholm of the Respiratory Effectiveness Group for moderating the steering committee meetings at which particle size nomenclature was discussed.",
year = "2018",
month = "4",
day = "30",
doi = "10.1089/jamp.2017.1396",
language = "English",
volume = "31",
pages = "111--113",
journal = "Journal of aerosol medicine and pulmonary drug delivery",
issn = "1941-2711",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

TY - JOUR

T1 - Harmonizing the Nomenclature for Therapeutic Aerosol Particle Size

T2 - A Proposal

AU - Hillyer, Elizabeth V

AU - Price, David B

AU - Chrystyn, Henry

AU - Martin, Richard J

AU - Israel, Elliot

AU - van Aalderen, Willem M C

AU - Papi, Alberto

AU - Usmani, Omar S

AU - Roche, Nicolas

N1 - Acknowledgements: The authors thank the other members of the Small Airways Study Group of the Respiratory Effectiveness Group who participated in discussions about nomenclature for therapeutic aerosol particle size: Dirkje Postma (University of Groningen, Department of Pulmonary Medicine and Tuberculosis, University Medical Center Groningen, the Netherlands, retired), Theresa Guilbert (Cincinnati Children's Hospital and Medical Center, Cincinnati, OH), Jonathan Grigg (Blizard Institute, Queen Mary University London, London, UK), and Wanda Phipatanakul (Boston Children's Hospital and Harvard Medical School, Boston, MA). They also thank Alison Chisholm of the Respiratory Effectiveness Group for moderating the steering committee meetings at which particle size nomenclature was discussed.

PY - 2018/4/30

Y1 - 2018/4/30

N2 - Total and regional airway deposition of orally inhaled drugs is determined by the complex interaction of numerous patient- and inhaler-related factors. Particle size (aerodynamic diameter) is considered to be the most important of the aerosol-related factors(1–3); however, the medical literature lacks standard nomenclature to distinguish aerosol particle sizes. There are clear differences in particle behavior and deposition according to size, and hence we believe a strong rationale for clearly denoting the aerosol particle size of orally inhaled, therapeutic aerosols, both in product descriptions and as part of the design and reporting of research in this area

AB - Total and regional airway deposition of orally inhaled drugs is determined by the complex interaction of numerous patient- and inhaler-related factors. Particle size (aerodynamic diameter) is considered to be the most important of the aerosol-related factors(1–3); however, the medical literature lacks standard nomenclature to distinguish aerosol particle sizes. There are clear differences in particle behavior and deposition according to size, and hence we believe a strong rationale for clearly denoting the aerosol particle size of orally inhaled, therapeutic aerosols, both in product descriptions and as part of the design and reporting of research in this area

KW - Letter to the Editor

U2 - 10.1089/jamp.2017.1396

DO - 10.1089/jamp.2017.1396

M3 - Article

VL - 31

SP - 111

EP - 113

JO - Journal of aerosol medicine and pulmonary drug delivery

JF - Journal of aerosol medicine and pulmonary drug delivery

SN - 1941-2711

IS - 2

ER -